Table 2.
The baseline data of all PI-DLBCL patients.
| Observed metrics | Number of cases (%) |
|---|---|
| Age(year) | |
| ≤60 | 51 (57.95) |
| >60 | 37 (42.05) |
| Gender | |
| Male | 60 (68.18) |
| Female | 28 (31.82) |
| ECOG score | |
| < 2 | 45 (51.14) |
| ≥2 | 43 (48.86) |
| Lugano staging | |
| Stage I-II | 34 (38.64) |
| Stage III-IV | 54 (61.36) |
| B symptoms | |
| Yes | 36 (40.91) |
| No | 52 (59.09) |
| Hans pathological classification | |
| GCB | 35 (39.77) |
| Non-GCB | 53 (60.23) |
| IPI score | |
| 0–2 | 42 (47.73) |
| 3–5 | 46 (52.27) |
| White blood cell count | |
| Normal | 72 (81.82) |
| Abnormal | 16 (18.18) |
| Serum LDH | |
| Normal | 58 (65.91) |
| Elevated | 30 (34.09) |
| Albumin | |
| ≥35 g/L | 58 (65.91) |
| <35 g/L | 30 (34.09) |
| β2 Microglobulin | |
| ≤3 μg/ml | 67 (76.14) |
| >3 μg/ml | 21 (23.86) |
| Ki-67(%) | |
| ≥80% | 66 (75.00) |
| <80% | 22 (25.00) |
| Lymphoma site | |
| Small intestinal group | 77 (87.50) |
| Non-small intestinal group | 11 (12.50) |
| First-line treatment | |
| Surgical group | 58 (65.91) |
| Non-surgical group | 30 (34.09) |